№ files_lp_3_process_9_43425
File format: docx
Character count: 4562
File size: 19 KB
This document provides detailed instructions for the administration of injectable glucagon (GVOKE HypoPen) during severe low blood sugar episodes in children with diabetes.
Year:
2020
Region / city:
United States
Subject:
Diabetes, Medical Emergency, Glucagon
Document Type:
Instructional Guide
Author:
Xeris Pharmaceuticals, Inc.
Intended Audience:
School Staff, Health Care Providers
Period of Validity:
Not specified
Approval Date:
March 15, 2021
Date of Changes:
Not specified
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Document type:
Medical procedure competency checklist
Medication:
GVOKE HypoPen (injectable glucagon)
Medical condition:
Severe hypoglycemia in students with diabetes
Setting:
School health services
Institutional context:
School health program
Responsible role:
School Nurse
Trained personnel:
School staff member
Target population:
Students with diabetes
Procedure type:
Emergency medication administration
Required documentation:
Student medication administration log
Emergency protocol:
Activation of 911 or emergency medical services
Training verification:
Initial demonstration and return demonstration
Authorization requirement:
Parent or guardian authorization
Monitoring requirement:
Observation of consciousness, pulse, respirations, and seizure activity
Post-administration actions:
Provide fast-acting sugar when student is able to swallow and report medication details to emergency responders
Disposal requirement:
Proper disposal of used medical materials
Follow-up:
Communication with parent or guardian and health care provider
Type of document:
Pharmaceutical Benefits Advisory Committee (PBAC) submission and assessment report
Medicine:
Aripiprazole long-acting injectable (AOM)
Dosage forms/strengths:
Powder for injection 300 mg (as monohydrate) with diluent in pre-filled dual-chamber syringe; Powder for injection 400 mg (as monohydrate) with diluent in pre-filled dual-chamber syringe
Brand:
Abilify Maintena
Sponsor:
Lundbeck Australia Pty Ltd
Purpose of submission:
Request for General Schedule Authority Required (STREAMLINED) PBS listing of AOM pre-filled syringe dose form
Indication:
Treatment of schizophrenia
Comparator:
AOM modified release injection vial kit (therapeutic vial kits)
Regulatory status:
TGA registered 7 May 2018 for acute and maintenance treatment of schizophrenia in adults and maintenance treatment of bipolar I disorder (monotherapy)
Previous PBAC consideration:
400 mg AOM PFS recommended July 2018; recommendation rescinded March 2023
Pricing basis:
Cost-minimisation versus AOM vial kit with equivalent pricing (no price premium)
Price levels referenced:
DPMQ, PTP, AEMP (current as of 1 June 2025)
Estimated PBS usage:
400,000 to <500,000 scripts over first six years (Year 1 10,000–<20,000; Year 6 100,457)
Indication listing conditions:
Authority Required (Streamlined); prescriber types include medical practitioners and nurse practitioners; general schedule (Code GE)
Version:
5
Agreed Date:
16/10/2024
Review Date:
16/10/2026
Geographic Scope:
Pan-London
Healthcare Setting:
Community setting
Clinical Area:
Palliative care
Document Type:
Medication authorisation and administration record
Medication Routes:
Subcutaneous injection; Intramuscular injection; Continuous subcutaneous infusion
Medication Use:
As required (PRN); Regular dosing; Crisis and emergency use
Patient Population:
Community patients receiving injectable symptom control medication
Responsible Professionals:
Authorising clinicians (GMC/NMC/GPhC registered)
Associated System:
NHS
Content Sections:
PRN injection charts; syringe pump authorisation charts; crisis and emergency injection records; regular dose injection records; controlled drug stock balance charts
Review Statement:
Subject to ongoing review to reflect emerging evidence
Year:
2010
Region / City:
Connecticut
Subject:
Pharmaceutical practice, Collaborative practice agreements, Antipsychotic therapy
Document Type:
Legal agreement, Clinical protocol
Organization / Institution:
Connecticut Department of Consumer Protection, University of Connecticut School of Pharmacy
Author:
C. Caley, PharmD, BCPP, Clinical Professor
Target Audience:
Pharmacists, Physicians, Healthcare providers in Connecticut
Effective Date:
October 1, 2010
Date of Approval:
Not specified
Date of Review:
Annual review completed
Date of Modification:
Not specified
Year:
not specified
Language:
English
Topic:
HIV-1 treatment
Therapeutic regimen:
Long-acting injectable antiretroviral therapy
Medication:
Cabenuva (cabotegravir and rilpivirine)
Drug classes:
Integrase strand transfer inhibitor; non-nucleoside reverse transcriptase inhibitor
Route of administration:
Intramuscular gluteal injection
Dosing schedules:
Every 4 weeks; every 8 weeks
Target population:
Adults with HIV-1 infection
Eligibility criteria:
Virologically suppressed patients without relevant drug resistance
Exclusion criteria:
Pregnancy, breastfeeding, specific drug interactions, hypersensitivity
Monitoring requirements:
HIV viral load, CMP, CBC
Clinical setting:
Clinic-administered therapy
Healthcare roles:
Provider, case manager, registered nurse, pharmacy
Regulatory reference:
FDA labeling
Source adaptation:
Ward 86 Long-Acting Injectable ARV Protocol
Year:
2018
Region / City:
Global
Topic:
Family Planning
Document Type:
Training Material
Institution:
CCP, WHO
Author:
Not specified
Target Audience:
Healthcare professionals, trainees
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Title:
Polysulfated Glycosaminoglycan (Adequan)
Active ingredient:
Polysulfated glycosaminoglycan (primarily chondroitin sulfate)
Brand name:
Adequan®
Source of substance:
Extracted from bovine tracheal tissue
Pharmaceutical form:
Injectable solution
Route of administration:
Intramuscular injection
Indications:
Arthritis; Feline lower urinary tract disease
Target species:
Dogs; Cats; Horses
Dosage regimen for arthritis:
Twice weekly for 4 weeks; maximum of eight injections
Pharmacological properties:
Cartilage matrix support; Anti-inflammatory activity; Promotion of joint fluid production
Contraindications:
Known bleeding disorders
Precautions:
Use with caution in patients with kidney disease; Not studied in pregnant or lactating animals
Adverse effects reported:
Injection site pain; Diarrhea; Increased bleeding tendency
Drug interactions:
None known
Related human comparison:
Pentosan polysulfate sodium in interstitial cystitis
Type of document:
Veterinary drug information sheet
Year:
2026
Region / City:
Not specified
Subject:
Pharmaceutical calculations, drug reconstitution
Document Type:
Educational worksheet
Institution / Organization:
Pharmacy education or training program
Author:
Not specified
Target Audience:
Pharmacy students or healthcare trainees
Period of validity:
2026
Date of preparation:
2026-02-27
Drug types covered:
Cefazolin, Ampicillin/Sulbactam, Amoxicillin, Ceftriaxone, Penicillin, Vancomycin, Zosyn, Streptomycin, Cefepime, Ceftazidime, Timentin, IVIG
Measurement units:
mL, g, mg/mL, MU
Application context:
Intravenous and oral drug reconstitution, dose calculation
Year:
2021
Region / City:
Global
Topic:
Progestin-Only Injectable Contraceptives
Document Type:
Training Manual
Organization:
Family Planning Training Resource
Author:
Unknown
Target Audience:
Health providers, facilitators, and trainers
Effective Period:
Ongoing
Approval Date:
Unknown
Modification Date:
Unknown
Year:
Not specified
Region / Countries:
Angola; Bangladesh; India; Tanzania; Burkina Faso; Burundi; DRC; Ethiopia; Ghana; Kenya; Madagascar; Mali; Mozambique; Niger; Pakistan; Rwanda; Senegal; Zambia; Malawi; Nigeria; Uganda
Thematic Area:
Family planning; DMPA-SC self-injection market development; Public and private sector health systems strengthening
Document Type:
Concept note template
Program:
AIMS Fund (Advancing Injectable Markets for Sustainability)
Implementing Organizations:
PATH; Africa Resource Centre; Health Systems Insight; Metrics for Management; Solina Centre for International Development and Research; AIMS Project Consortium
Funding Amount:
Up to US$200,000
Grant Duration:
9 months
Eligible Applicants:
Local not-for-profit nongovernmental organizations in eligible countries
Funding Cycle:
Two cycles per year; two to three grants per cycle
Application Process:
Competitive funding cycle; submission by email in MS Word format
Ineligible Activities:
Procurement of DMPA-SC; routine service delivery; research requiring ethical or external review approval
Contact Email:
[email protected]
Year:
2024
Region:
Massachusetts, USA
Subject:
Healthcare billing, Antipsychotic medications
Document Type:
Policy / Instruction
Organization:
MassHealth
Audience:
In-state acute inpatient hospital providers
Effective Date:
5/15/2024
Reference:
Sections 5.B.4.g of the MassHealth Acute Hospital Request for Applications
Medication Covered:
Long-Acting Injectable (LAI) Antipsychotics
Billing Codes:
National Drug Code (NDC), HCPCS
Submission Requirements:
Professional claims (Claim Types M and B), Direct Data Entry for IC drugs, invoice attachment from distributor/manufacturer
Payment Methodology:
Fee schedule in 101 CMR 317.00 or Individual Consideration (IC)
Documentation:
Attachments via Provider Online Service Center (POSC)
Compliance Notes:
Failure to follow instructions may result in inaccurate payment
Instruction Updates:
May be updated from time to time
Year:
2023
Region / city:
South Korea
Field:
Biomedical Science, Rehabilitation Technology
Document Type:
Press Release
Organization:
Institute for Basic Science (IBS)
Authors:
Subin Jin, Heewon Choi, Duhwan Seong, Chang-Lim You, Jong-Sun Kang, Seunghyok Rho, Won Bo Lee, Donghee Son, Mikyung Shin
Target Audience:
Researchers, Medical Professionals, Technology Developers
Period of Validity:
N/A
Approval Date:
1 November 2023
Date of Changes:
N/A
Document type:
Medical procedure competency checklist
Medication:
GVOKE HypoPen (injectable glucagon)
Medical condition:
Severe hypoglycemia in students with diabetes
Setting:
School health services
Institutional context:
School health program
Responsible role:
School Nurse
Trained personnel:
School staff member
Target population:
Students with diabetes
Procedure type:
Emergency medication administration
Required documentation:
Student medication administration log
Emergency protocol:
Activation of 911 or emergency medical services
Training verification:
Initial demonstration and return demonstration
Authorization requirement:
Parent or guardian authorization
Monitoring requirement:
Observation of consciousness, pulse, respirations, and seizure activity
Post-administration actions:
Provide fast-acting sugar when student is able to swallow and report medication details to emergency responders
Disposal requirement:
Proper disposal of used medical materials
Follow-up:
Communication with parent or guardian and health care provider
Year:
2024
Region / City:
Massachusetts
Topic:
Long-Acting Injectable Antipsychotic Medications
Document Type:
MassHealth Drug List Update
Institution:
MassHealth
Author:
MassHealth
Target Audience:
Healthcare providers, inpatient psychiatric service providers
Effective Period:
May 15, 2024
Approval Date:
May 15, 2024
Update Date:
Ongoing updates
Applicable Policy:
Long-Acting Injectable Antipsychotic Medication Payment and Reimbursement Policy
J-Codes:
J0401, J0402, J1631, J1943, J1944, J2358, J2426, J2427, J2428, J2680, J2794, J2798, J2799, J2801
Billing Instructions:
Available on the MassHealth website